The FDA reviews IND applications to ensure that the proposed clinical trials will not expose humans to unreasonable risks. The agency evaluates the toxicology data to ensure that the studies are adequate and that the proposed dosing in humans is justified. The FDA may request additional studies or halt a trial if safety concerns arise.
